Portal vein resection in pancreatic neuroendocrine neoplasms

• Verfasst von: Nießen, Anna [VerfasserIn]
• Verfasst von: Klaiber, Ulla [VerfasserIn]
• Verfasst von: Lewosinska, Magdalena [VerfasserIn]
• Verfasst von: Nickel, Felix [VerfasserIn]
• Verfasst von: Billmann, Franck [VerfasserIn]
• Verfasst von: Hinz, Ulf [VerfasserIn]
• Verfasst von: Büchler, Markus W. [VerfasserIn]
• Verfasst von: Hackert, Thilo [VerfasserIn]
• Titel: Portal vein resection in pancreatic neuroendocrine neoplasms
• Verf.angabe: Anna Nießen, MD, Ulla Klaiber, MD, Magdalena Lewosinska, MD, Felix Nickel, MD, Franck Billmann, MD, Ulf Hinz, MSc, Markus W. Büchler, MD, Thilo Hackert, MD
• E-Jahr: 2024
• Jahr: April 2024
• Umfang: 8 S.
• Illustrationen: Illustrationen
• Fussnoten: Online verfügbar: 22. Januar 2024, Artikelversion: 15. März 2024 ; Gesehen am 10.10.2024
• Titel Quelle: Enthalten in: Surgery
• Ort Quelle: Amsterdam [u.a.] : Elsevier, 1995
• Jahr Quelle: 2024
• Band/Heft Quelle: 175(2024), 4 vom: Apr., Seite 1154-1161
• ISSN Quelle: 1532-7361
• DOI: doi:10.1016/j.surg.2023.12.020
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1905346212

Abstract

Background - Surgery offers the only cure for borderline resectable or locally advanced pancreatic neuroendocrine neoplasms. Data on incidence, perioperative and long-term outcomes of portal vein resection for pancreatic neuroendocrine neoplasms are scarce. This study aimed to analyze the outcome and prognostic factors of portal vein resection in surgery for pancreatic neuroendocrine neoplasms. - Methods - Consecutive patients were analyzed. Portal vein resection was classified according to the International Study Group of Pancreatic Surgery. Clinicopathologic features and overall and disease-free survival were assessed and compared with standard resection in a matched-pair analysis. - Results - A total of 54 of 666 (8%) resected pancreatic neuroendocrine neoplasms patients underwent portal vein resection, including 7 (13%) tangential resections with venorrhaphy (type 1), 2 (4%) patch reconstructions (type 2), 35 (65%) end-to-end anastomoses (type 3), and 10 (19%) graft interpositions (type 4); 52% of those underwent pancreatoduodenectomy, 22% distal pancreatectomy, and 26% total pancreatectomy. Postoperative portal vein thrombosis occurred in 19%. Postoperative pancreatic fistula grades B and C (9% vs 16%; P = .357), complications Clavien-Dindo grade ≥IIIb (28% vs 13%; P = .071), and 90-day mortality rate (2% each) were not significantly different compared with 108 matched patients. The 5-year overall survival was 45% (standard resection: 68%; P = .432), and the 5-year disease-free survival was 25% (standard resection: 34%; P = .716). Radical resection was associated with 5-year overall survival of 51% and 5-year disease-specific survival of 75%. - Conclusion - This is the largest single-center analysis evaluating perioperative and long-term outcomes of portal vein resection for pancreatic neuroendocrine neoplasms. The postoperative complication rate after portal vein resection is comparable with standard resection. The 90-day mortality is low. Radical resection leads to excellent 5-year oncological survival.